The recent insider purchase signals confidence in the company's future, despite its lack of profit over the past year. Insider ownership shows some alignment between management and smaller shareholders.
Despite Health Catalyst's subdued growth projections, it trades at a P/S ratio similar to the industry, indicating investors' willingness to pay for exposure. However, this could lead to disappointment if the P/S falls in line with the growth outlook, potentially impacting share prices.
Despite Health Catalyst's shares moving up, the company's muted revenue growth estimates cast doubt on whether the current P/S ratio is justifiable, risking a possible decline.
Over the past year, insider activities in Health Catalyst show optimism for the company's future. The significant percentage of company shares held by insiders exhibits alignment between management and smaller shareholders.
Health Catalyst's financials, despite a strong balance sheet and potential for growth investments, are marred by its operating loss and lack of positive cash-flow, raising its risk profile.
Insider trading suggests optimism for the company's future due to more stock purchases than sales. Notably, CEO Daniel Burton's share purchases showcase confidence in the company's current value.
Q2 was weaker than expected for data analytics stocks resulting in a 17.6% average share price decrease. The industry outlook appears bearish as investors are valuing profits over growth.
ヘルス カタリストに関するコメント
• $ボックス A(BOX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $CF インダストリーズ ホールディングス(CF.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $135 (from $110)
• $ニュー ゴールド(NGD.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $1.25 (from $1)
• $センセイ バイオセラピューティクス(SNSE.US)$: Oppenheimer Upgrades to Outperform from Perform - PT $5
• $Senetas Corp Ltd(SEN.AU)$ : Tru...
• $CDW(CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $コルテバ(CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $コアシビック(CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $デルタ エアー ラインズ(DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $エイチ ビー フラー(FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $ハンチントン インゴールズ インダストリーズ(HII.US)$ : Cowen U...
まだコメントはありません